MaaT Pharma stock jumps 11% after DSMB clears Phase 2b trial to continue
PositiveFinancial Markets

MaaT Pharma's stock surged by 11% following the announcement that the Data Safety Monitoring Board (DSMB) has approved the continuation of its Phase 2b trial. This is significant as it reflects confidence in the company's clinical research and potential for future treatments, which could lead to advancements in patient care and increased investor interest.
— Curated by the World Pulse Now AI Editorial System